Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.
The association of B7-1/CD28 between antigen presenting cells (APCs) and T-cells provides a second signal to proliferate and activate T-cell immunity at the induction phase. Many reports indicate that tumor cells transfected with B7-1 induced augmented antitumor immunity at the induction phase by mi...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4226464?pdf=render |
| _version_ | 1819183201947484160 |
|---|---|
| author | Xiao-Lin Li Marjolein Sluijter Elien M Doorduijn Shubha P Kale Harris McFerrin Yong-Yu Liu Yan Li Madhusoodanan Mottamal Xin Yao Fengkun Du Baihan Gu Kim Hoang Yen H Nguyen Nichelle Taylor Chelsea R Stephens Thorbald van Hall Qian-Jin Zhang |
| author_facet | Xiao-Lin Li Marjolein Sluijter Elien M Doorduijn Shubha P Kale Harris McFerrin Yong-Yu Liu Yan Li Madhusoodanan Mottamal Xin Yao Fengkun Du Baihan Gu Kim Hoang Yen H Nguyen Nichelle Taylor Chelsea R Stephens Thorbald van Hall Qian-Jin Zhang |
| author_sort | Xiao-Lin Li |
| collection | DOAJ |
| description | The association of B7-1/CD28 between antigen presenting cells (APCs) and T-cells provides a second signal to proliferate and activate T-cell immunity at the induction phase. Many reports indicate that tumor cells transfected with B7-1 induced augmented antitumor immunity at the induction phase by mimicking APC function; however, the function of B7-1 on antitumor immunity at the effector phase is unknown. Here, we report direct evidence of enhanced T-cell antitumor immunity at the effector phase by the B7-1 molecule. Our experiments in vivo and in vitro indicated that reactivity of antigen-specific monoclonal and polyclonal T-cell effectors against a Lass5 epitope presented by RMA-S cells is increased when the cells expressed B7-1. Use of either anti-B7-1 or anti-CD28 antibodies to block the B7-1/CD28 association reduced reactivity of the T effectors against B7-1 positive RMA-S cells. Transfection of Lass5 cDNA into or pulse of Lass5 peptide onto B7-1 positive RMA-S cells overcomes the requirement of the B7-1/CD28 signal for T effector response. To our knowledge, the data offers, for the first time, strong evidence that supports the requirement of B7-1/CD28 secondary signal at the effector phase of antitumor T-cell immunity being dependent on the density of an antigenic peptide. |
| first_indexed | 2024-12-22T22:58:16Z |
| format | Article |
| id | doaj.art-f19ef3458ca444f3bfe66781882d6c97 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T22:58:16Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f19ef3458ca444f3bfe66781882d6c972022-12-21T18:09:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01911e10819210.1371/journal.pone.0108192Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.Xiao-Lin LiMarjolein SluijterElien M DoorduijnShubha P KaleHarris McFerrinYong-Yu LiuYan LiMadhusoodanan MottamalXin YaoFengkun DuBaihan GuKim HoangYen H NguyenNichelle TaylorChelsea R StephensThorbald van HallQian-Jin ZhangThe association of B7-1/CD28 between antigen presenting cells (APCs) and T-cells provides a second signal to proliferate and activate T-cell immunity at the induction phase. Many reports indicate that tumor cells transfected with B7-1 induced augmented antitumor immunity at the induction phase by mimicking APC function; however, the function of B7-1 on antitumor immunity at the effector phase is unknown. Here, we report direct evidence of enhanced T-cell antitumor immunity at the effector phase by the B7-1 molecule. Our experiments in vivo and in vitro indicated that reactivity of antigen-specific monoclonal and polyclonal T-cell effectors against a Lass5 epitope presented by RMA-S cells is increased when the cells expressed B7-1. Use of either anti-B7-1 or anti-CD28 antibodies to block the B7-1/CD28 association reduced reactivity of the T effectors against B7-1 positive RMA-S cells. Transfection of Lass5 cDNA into or pulse of Lass5 peptide onto B7-1 positive RMA-S cells overcomes the requirement of the B7-1/CD28 signal for T effector response. To our knowledge, the data offers, for the first time, strong evidence that supports the requirement of B7-1/CD28 secondary signal at the effector phase of antitumor T-cell immunity being dependent on the density of an antigenic peptide.http://europepmc.org/articles/PMC4226464?pdf=render |
| spellingShingle | Xiao-Lin Li Marjolein Sluijter Elien M Doorduijn Shubha P Kale Harris McFerrin Yong-Yu Liu Yan Li Madhusoodanan Mottamal Xin Yao Fengkun Du Baihan Gu Kim Hoang Yen H Nguyen Nichelle Taylor Chelsea R Stephens Thorbald van Hall Qian-Jin Zhang Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. PLoS ONE |
| title | Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. |
| title_full | Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. |
| title_fullStr | Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. |
| title_full_unstemmed | Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. |
| title_short | Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. |
| title_sort | limited density of an antigen presented by rma s cells requires b7 1 cd28 signaling to enhance t cell immunity at the effector phase |
| url | http://europepmc.org/articles/PMC4226464?pdf=render |
| work_keys_str_mv | AT xiaolinli limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT marjoleinsluijter limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT elienmdoorduijn limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT shubhapkale limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT harrismcferrin limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT yongyuliu limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT yanli limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT madhusoodananmottamal limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT xinyao limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT fengkundu limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT baihangu limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT kimhoang limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT yenhnguyen limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT nichelletaylor limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT chelsearstephens limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT thorbaldvanhall limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase AT qianjinzhang limiteddensityofanantigenpresentedbyrmascellsrequiresb71cd28signalingtoenhancetcellimmunityattheeffectorphase |